The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Six months after suffering a life-threatening stroke, a man achieved his goals of walking his daughter down the aisle and dancing the merengue with her at the wedding. BRANDON, Fla. - For Manuel Vera, ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

From a certain high-heeled Mouse to the tiny version of our favorite candy, just the idea of "mini" is psychologically ...